A $4.8 Billion Reason to Buy BioMarin Stock Today

Core Viewpoint - BioMarin has announced a $4.8 billion acquisition of Amicus Therapeutics, significantly enhancing its position in the rare disease market with a focus on established therapies [1][3][4] Group 1: Acquisition Details - The acquisition is an all-cash transaction valuing Amicus shares at $14.50, representing a 33% premium over the previous close [1] - The deal is expected to close in the second quarter of 2026 and is projected to be accretive to non-GAAP diluted earnings per share within the first 12 months [5] Group 2: Financial Impact - The acquisition immediately expands BioMarin's commercial portfolio with two established treatments, Galafold and Pombiliti-Opfolda, which generated nearly $600 million in combined net product revenues last year [3] - Bloomberg Intelligence projects potential combined sales from these therapies to reach $1.4 billion by the end of the decade, diversifying BioMarin's revenue base and reducing reliance on Voxzogo [4] Group 3: Market Position and Future Outlook - The deal positions BioMarin to leverage the strong pricing power and limited competition in the rare disease therapeutics market, ensuring market durability [6] - Wall Street analysts maintain a "Moderate Buy" rating on BioMarin, with price objectives suggesting potential upside of 100% through the end of 2026 [7]